Articles with public access mandates - Tanuja BordiaLearn more
Not available anywhere: 2
Continuous and intermittent nicotine treatment reduces L-3, 4-dihydroxyphenylalanine (L-DOPA)-induced dyskinesias in a rat model of Parkinson's disease
T Bordia, C Campos, L Huang, M Quik
Journal of Pharmacology and Experimental Therapeutics 327 (1), 239-247, 2008
Mandates: US National Institutes of Health
Nicotine and nicotinic receptor drugs: potential for Parkinson's disease and drug-induced movement disorders
M Quik, T Bordia, D Zhang, XA Perez
International review of neurobiology 124, 247-271, 2015
Mandates: US National Institutes of Health
Available somewhere: 4
Nicotine as a potential neuroprotective agent for Parkinson's disease
M Quik, XA Perez, T Bordia
Movement disorders 27 (8), 947-957, 2012
Mandates: US National Institutes of Health
Multiple roles for nicotine in Parkinson's disease
M Quik, LZ Huang, N Parameswaran, T Bordia, C Campos, XA Perez
Biochemical pharmacology 78 (7), 677-685, 2009
Mandates: US National Institutes of Health
Alpha7 nicotinic receptors as therapeutic targets for Parkinson's disease
M Quik, D Zhang, M McGregor, T Bordia
Biochemical pharmacology 97 (4), 399-407, 2015
Mandates: US National Institutes of Health, UK Medical Research Council, Wellcome Trust
Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias
T Bordia, XA Perez, JE Heiss, D Zhang, M Quik
Neurobiology of disease 91, 47-58, 2016
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program